§ 530.13. Extralabel use from compounding of approved new animal and approved human drugs.
228 words·~1 min read·
/us/cfr/t21/s§ 530.13·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)This part applies to compounding of a product from approved animal or human drugs by a veterinarian or a pharmacist on the order of a veterinarian within the practice of veterinary medicine. Nothing in this part shall be construed as permitting compounding from bulk drugs.
(b)Extralabel use from compounding of approved new animal or human drugs is permitted if:
(1)All relevant portions of this part have been complied with;
(2)There is no approved new animal or approved new human drug that, when used as labeled or in conformity with criteria established in this part, will, in the available dosage form and concentration, appropriately treat the condition diagnosed. Compounding from a human drug for use in food-producing animals will not be permitted if an approved animal drug can be used for the compounding;
(3)The compounding is performed by a licensed pharmacist or veterinarian within the scope of a professional practice;
(4)Adequate procedures and processes are followed that ensure the safety and effectiveness of the compounded product;
(5)The scale of the compounding operation is commensurate with the established need for compounded products (e.g., similar to that of comparable practices); and
(6)All relevant State laws relating to the compounding of drugs for use in animals are followed.
(c)Guidance on the subject of compounding may be found in guidance documents issued by FDA.
Connections1 cite this
Cited by 1 section
Citation graph
cites case law
§ 530.13
Extralabel use from compounding of approved new animal and approved human drugs.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source